Skip to content
value.today

Cyteir Therapeutics, Inc.

Total raised
$112 M
4 rounds on record
Latest round
$80 M
Feb 2021
First round on record
Oct 2015
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cyteir Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$80 MNo. 4$50 to $250 million

Cyteir Therapeutics, Inc.: Raise no. 4, Feb 2021

Investors in this round

22 investors had bought by the notice of Feb 17, 2021: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Cyteir Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$80 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew S. Gengos · Executive Officer
  • Markus Renschler · Executive Officer, Director
  • Paul S. Secrist · Executive Officer
  • Janwillem Naesens · Director
  • Jean George · Director
  • Joseph S. Zakrzewski · Director
  • Karen Hong · Director
  • Racquel Bracken · Director
  • Susan S. Molineaux · Director
  • Timothy S. Romberger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Markus Renschler, President and chief executive officer. Newest notice filed Feb 17, 2021. Read the notice at the SEC.

equitySEC
Sep 2019$20 MNo. 3$10 to $50 million

Cyteir Therapeutics, Inc.: Raise no. 3, Sep 2019

Investors in this round

6 investors had bought by the notice of Oct 15, 2019: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Cyteir Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Markus Renschler · Executive Officer, Director
  • Timothy Romberger · Executive Officer, Director
  • Janwillem Naesens · Director
  • Jean George · Director
  • Karen Hong · Director
  • Racquel Bracken · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Markus Renschler, President and chief executive officer. Newest notice filed Oct 15, 2019. Read the notice at the SEC.

equitySEC
Jan 2018$6 MNo. 2$2 to $10 million

Cyteir Therapeutics, Inc.: Raise no. 2, Jan 2018

Investors in this round

12 investors had bought by the notice of May 16, 2018: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Cyteir Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $35 M offered; $29 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,360,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Markus Renschler · Executive Officer, Director
  • Ronald Goldstein · Executive Officer
  • Timothy Romberger · Executive Officer, Director
  • Bart Van Hooland · Director
  • Jean George · Director
  • Racquel Bracken · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS Securities, LLC (CRD 104059) · New York, New YorkSold in CA, NY, PA

Remarks in the notice

  • On fees: “Subject to future issuances.”

Signed by Markus Renschler, President and CEO. Newest notice filed May 16, 2018 (1 amendment). Read the notice at the SEC.

equitySEC
Oct 2015$6 MNo. 1$2 to $10 million

Cyteir Therapeutics, Inc.: Raise no. 1, Oct 2015

Investors in this round

15 investors had bought by the notice of Nov 16, 2016: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Cyteir Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donald Corcoran · Executive Officer, Director
  • Kevin Mills · Executive Officer, Director
  • Ronald Goldstein · Executive Officer
  • Barry Mills · Director
  • Markus Renschler · Director
  • Timothy Romberger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Donald Corcoran, President and CEO. Newest notice filed Nov 16, 2016 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cyteir Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).

    SEC Form D · Feb 2021

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Feb 2021

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Cyteir Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
DF II GP SarlOthernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Ihl SACompanynot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Timothy RombergerPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2021)SEC Form 3
Venrock Associates VII, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Venrock Management VII, LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Venrock Partners VII, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Wepaven BVOthernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cyteir Therapeutics, Inc.
NameRoleNamed in
Andrew S. GengosExecutive officerFeb 2021
Markus RenschlerExecutive officerFeb 2021
Paul S. SecristExecutive officerFeb 2021
Timothy RombergerExecutive officerOct 2019
Ronald GoldsteinExecutive officerMay 2018
Donald CorcoranExecutive officerNov 2016
Kevin MillsExecutive officerNov 2016
William B. Asher, Jr.Executive officerDec 2015
Janwillem NaesensDirectorFeb 2021
Jean GeorgeDirectorFeb 2021
Joseph S. ZakrzewskiDirectorFeb 2021
Karen HongDirectorFeb 2021
Markus RenschlerDirectorFeb 2021
Racquel BrackenDirectorFeb 2021
Susan S. MolineauxDirectorFeb 2021
Timothy S. RombergerDirectorFeb 2021
Timothy RombergerDirectorOct 2019
Bart Van HoolandDirectorMay 2018
Barry MillsDirectorNov 2016
Donald CorcoranDirectorNov 2016
Kevin MillsDirectorNov 2016
Barry B. MillsDirectorDec 2015
Timothy B. RombergerDirectorDec 2015